What's in Sinovac Biotech Co., Ltd's pipeline?

Sinovac Biotech Co., Ltd has 64 drugs in our index: 39 marketed, 0 filed, 15 in Phase 3, 2 in Phase 2, 8 in Phase 1.

Which companies overlap with Sinovac Biotech Co., Ltd's portfolio?

Top competitors by shared drug class: Sanofi Pasteur, a Sanofi Company, GlaxoSmithKline, Merck Sharp & Dohme LLC, Seqirus, Centers for Disease Control and Prevention.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sinovac-biotech-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sinovac Biotech Co., Ltd — Portfolio Competitive Intelligence Brief

Sinovac Biotech Co., Ltd pipeline: 39 marketed, 0 filed, 15 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

39 marketed 0 filed 15 Phase 3 2 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
3wIPV	3wIPV	marketed
whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose	whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose	marketed
EV71 inactived vaccine（Human diploid cells）	EV71 inactived vaccine（Human diploid cells）	marketed
split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose	split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose	marketed
Healive® Lot 2	Healive® Lot 2	marketed
Experimental 23-valent PPV	Experimental 23-valent PPV	marketed
Healive+Havrix	Healive+Havrix	marketed	Inactivated viral vaccine combination	Immunology / Infectious Disease
3sIPV	3sIPV	marketed
Healive® Lot 1	Healive® Lot 1	marketed
Experimental 23-valent Pneumococcal	Experimental 23-valent Pneumococcal	marketed
Experimental Vaccine	Experimental Vaccine	marketed
Concomitant administration of EV71vaccine with EPI vaccines	Concomitant administration of EV71vaccine with EPI vaccines	marketed

Therapeutic area mix

Immunology / Infectious Disease · 18
Immunology · 15
Infectious Diseases · 2
Infectious Disease · 1
Infectious disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi Pasteur, a Sanofi Company · 10 shared drug classes
GlaxoSmithKline · 8 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
Seqirus · 5 shared drug classes
Centers for Disease Control and Prevention · 5 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 5 shared drug classes
Sanofi · 5 shared drug classes
Il-Yang Pharm. Co., Ltd. · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sinovac Biotech Co., Ltd:

Cite this brief

Drug Landscape (2026). Sinovac Biotech Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sinovac-biotech-co-ltd. Accessed 2026-05-16.